MDR class IIa approved
Certified for Europe
ISO 13485 certified
MDR class IIa approved
CE (0344) certified
ISO 13485 certified
Next level eye care diagnostics
With global costs of vision loss estimated to be nearly $3 trillion and up to 80% cases of retinal diseases causing visual impairment or blindness that can often be prevented if detected timely, artificial intelligence opens up a whole new possibilities in eye care. Imaging is non-invasive and reliable screening method but requires expertise to analyse/read the acquired images. Using artificial intelligence, this can be done quickly, yet accurately.
RetCAD™ uses state-of-the-art deep learning and computer vision technology utilizing a large amount of retinal images in order to provide precisely quantified clinical evidence. The software assists eye care specialists in early diagnosis and grading of vision threatening diseases, such as Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). Simplified visualization of the scan analysis with heat maps help improve patient engagement and prevent severe eyesight problems and blindness.
Consistent performance with better patient care
Minimized screening and diagnostic lead times
Output conform international standards such as ICDR and AREDS
Customized integration to user specific workflows
Standardized reporting with a simple graphic representation
Applications

Medical centers and
eye care specialists
Fast and effective patient triaging

Optical retail and digital healthcare services
Instant detection of early symptoms
Detection for Diabetic Retinopathy and Age-related Macular Degeneration can be now performed by opticians using artificial intelligence to help spot early signs of the diseases and save diagnostics costs.
RetCAD™ software integrated with a fundus camera ensures reliable and consistent performance, irrespective of the reader, workload or time of day. Disease symptoms detection takes only few minutes and provides validated results instantly.

Large national screening programs and research
Helping more patients faster
With use of artificial intelligence healthcare organisations can perform mass examinations on a large scale with very accurate results, on pair or even surpassing the performance of traditional vision screening methods.
Having every patient scan instantly analyzed with a clinically validated software system trained to detect typical disease patterns, RetCAD™ allows for screening big populations fast while providing highly reliable results.
How it works
With today’s digital color fundus cameras, one or multiple images can be acquired from a patient within seconds and are presented on the operator’s computer screen. RetCAD™ will automatically start analysing any acquired color fundus image and provide the user with a score and heat map that indicate referable disease symptoms.
RetCAD™ is GDPR compliant and analyzes pseudo-anonymized data to make sure patient privacy is preserved.
Processing/analysis on the Thirona servers with RetCAD™ AI takes approximately 1 minute.
Results are returned and imported to client application to be accessed directly in the application.
The intuitive visual format of the report allows quick and easy interpretation of the results by the eye care specialist.
Download the white paper to learn more on the general principles of the software and the performance in comparison to human experts, on various datasets.
Demo

RetCAD™ is a MDR class IIa CE 0344-certified software product using Artificial Intelligence that analyses color fundus images for the presence of Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR).
Available on pay-per-use basis RetCAD™ is used in hospitals, eye care clinics, screening programs and optical stores for early detection of retinal diseases.
Papers & Publications
Learn more about the performance of RetCAD™ through below validation studies.
Genetic risk score has added value over initial clinical grading stage in predicting disease progression in age-related macular degeneration | Apr 2019 | Nature Scientific reports